Wall Street Zen Downgrades Repligen to Hold Rating

Analysts cite concerns over price target reduction and mixed analyst sentiment on the stock.

Published on Feb. 28, 2026

Got story updates? Submit your updates here. ›

Wall Street Zen, an equity research firm, has downgraded shares of Repligen Corporation (NASDAQ:RGEN) from a "buy" rating to a "hold" rating in a new report. The downgrade comes as several other analysts have also recently adjusted their price targets and ratings on the biotech company.

Why it matters

Repligen is a key player in the bioprocessing and biopharmaceutical equipment market, so changes in analyst sentiment can impact investor confidence and the company's stock price performance. The downgrade highlights some near-term uncertainty around Repligen's growth trajectory.

The details

In its report, Wall Street Zen lowered its price target on Repligen shares from $200 to $195, while also shifting its rating from "buy" to "hold." The research firm cited a mixed bag of analyst views on the stock, with some maintaining bullish stances while others have become more cautious. Repligen's latest quarterly results also showed slowing revenue growth compared to previous periods.

  • Wall Street Zen issued its downgrade report on Saturday, February 28, 2026.

The players

Repligen Corporation

A life sciences company that develops and manufactures high-value consumable products for bioprocessing applications, specializing in technologies that support the development and production of biopharmaceuticals.

Wall Street Zen

An equity research firm that provides investment analysis and ratings on public companies.

Got photos? Submit your photos here. ›

What’s next

Investors will be watching to see if Repligen can regain analyst confidence and whether the company's growth trajectory stabilizes in the coming quarters.

The takeaway

The downgrade of Repligen by Wall Street Zen highlights the volatility and uncertainty that can impact even well-established biotech companies, underscoring the importance of closely monitoring analyst sentiment and financial performance when evaluating investment opportunities in this sector.